Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine

American Journal of Cancer Research

Volumn 6, Issue 1, 2016, Pages 84-90

  Li, Xiaoping ^a   Wang, Kun ^b   Zheng, Leizhen ^a   Meng, Zhiqiang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

High intensity focused ultrasound therapy; Pancreatic neoplasm; S 1

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BURN; CANCER CONTROL; CANCER PAIN; CANCER PROGNOSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH INTENSITY FOCUSED ULTRASOUND DEVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC PANCREAS CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; VISUAL ANALOG SCALE; VOMITING;

EID: 84976232089     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tschoep-Lechner KE, Milani V, Berger F, Dieterle N, Abdel-Rahman S, Salat C, Issels RD. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia 2013; 29: 8-16.
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
3. Hayashi K, Imaizumi T, Uchida K, Kuramochi H, Takasaki K. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1. Oncol Rep 2002; 9: 1355-61.
4. Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemother Pharmacol 2015; 75: 457-64.
5. Kawashima H, Itoh A, Ohno E, Nakamura M, Miyahara R, Ohmiya N, Hara K, Kanamori A, Itoh T, Taki T, Hirai T, Hashimoto S, Takeda K, Goto H, Hirooka Y. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 677-83.
6. Xiaoping L, Leizhen Z. Advances of high intensity focused ultrasound (HIFU) for pancreatic cancer. Int J Hyperthermia 2013; 29: 678-82.
7. Sofuni A, Moriyasu F, Sano T, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Ikeuchi N, Tanaka R, Umeda J, Tonozuka R, Honjo M, Mukai S, Fujita M, Itoi T. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J Gastroenterol 2014; 20: 9570-7.
8. Zhao H, Yang G, Wang D, Yu X, Zhang Y, Zhu J, Ji Y, Zhong B, Zhao W, Yang Z, Aziz F. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs 2010; 21: 447-52.
9. Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, Tsuchiya Y, Baba H, Ishii H, Omuro Y, Sho M, Matsumoto S, Yamada N, Yanagimoto H, Unno M, Ichikawa Y, Takahashi S, Watanabe G, Wakabayashi G, Egawa N, Tsuda M, Hosotani R, Hamada C, Hyodo I. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015; 112: 1428-34.
10. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-81.
11. Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20: 15110-8.
12. Ge F, Xu N, Bai Y, Ba Y, Zhang Y, Li F, Riess H, Oettle H. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist 2014; 19: 1133-4.
13. Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. J Gastrointest Cancer 2014; 45: 307-11.
14. Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol 2013; 72: 985-90.
15. Kim HJ, Yun J, Kim HJ, Kim KH, Kim SH, Lee TH, Lee SC, Bae SB, Kim CK, Lee NS, Moon JH, Park SH, Lee KT, Park SK, Won JH, Park HS, Hong DS. Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncol Lett 2012; 3: 1314-8.
16. Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Cancer Chemother Pharmacol 2012; 69: 957-64.
17. Luo J, Ren X, Yu T. Efficacy of extracorporeal ultrasound-guided high intensity focused ultrasound: An evaluation based on controlled trials in China. Int J Radiat Biol 2015; 91: 480-5.
18. Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract 2014; 2014: 205325.
19. Gao HF, Wang K, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Wang P, Shi WD, Sheng YH. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology 2013; 60: 1906-10.
20. Khokhlova TD, Hwang JH. HIFU for palliative treatment of pancreatic cancer. J Gastrointest Oncol 2011; 2: 175-84.
21. Orgera G, Monfardini L, Della VP, Zhang L, Bonomo G, Arnone P, Padrenostro M, Orsi F. High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results. Radiol Med 2011; 116: 734-48.
22. Wang K, Chen Z, Meng Z, Lin J, Zhou Z, Wang P, Chen L, Liu L. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia 2011; 27: 101-7.
23. Staruch RM, Hynynen K, Chopra R. Hyperthermia-mediated doxorubicin release from thermosensitive liposomes using MR-HIFU: therapeutic effect in rabbit Vx2 tumours. Int J Hyperthermia 2015; 31: 118-33.
24. Li CC, Wang YQ, Li YP, Li XL. High-intensity focused ultrasound for treatment of pancreatic cancer: a systematic review. J Evid Based Med 2014; 7: 270-81.
25. Wu F. High intensity focused ultrasound: a noninvasive therapy for locally advanced pancreatic cancer. World J Gastroenterol 2014; 20: 16480-8.